Life Sciences

Biotechnology

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

Take a closer look:

• Beyond borders: global biotech report 2012
• Progressions 2012: health care everywhere
• German biotechnology report 2011
• Progressions 2011: Pharma 3.0
• Beyond Borders 2011: global biotechnology report
• What Europe has to offer biotechnology companies
• 2011 Italian Biotechnology Report

Pharmaceutical

Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

Take a closer look:

• Progressions 2012: health care everywhere
• Progressions 2011: Pharma 3.0
• Cash on prescription 2012: pharmaceutical companies and working capital
• Cash on prescription 2011: pharmaceutical companies and working capital

Medical technology

Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

Take a closer look:

• Medical technology report 2011
• Medical technology report 2012